Advancing Next Gen Antibodies and ADCs: From AI Driven Cell Line Development to Integrated Manufacturing

Antibody-drug conjugate (ADC) development continues to evolve, with increased molecular complexity leading to new opportunities and challenges across design, development, and manufacturing. The industry is advancing novel technologies to support these next-generation antibody therapies and is adopting workflows better suited to their unique development considerations.

In this webinar, we will examine how development teams address these challenges through more integrated and data driven CMC strategies. We will focus on how AI driven cell line development is enabling faster clone selection, improved productivity, and earlier insight into product quality risks. We will cover key considerations from early process development through scale up and manufacturing and how these approaches enable consistency, efficiency, and commercialization readiness, with insights applicable to emerging formats such as multi-specific antibodies and ADCs.

The session will conclude with perspectives on the future of ADC manufacturing and bioproduction for complex molecules. It will highlight how AI, bioprocess integration, and digital connectivity may enable more predictive development and integrated manufacturing platforms. Attendees will gain insight into how emerging technologies can help de risk next generation programs while accelerating timelines and supporting long term manufacturing readiness.

Key Learning Objectives
~ Understand how increasing molecular complexity is reshaping CMC requirements across the development and manufacturing lifecycle
~ Learn how AI driven cell line development and robust manufacturing strategies are enabling more efficient and robust development and control of critical quality attributes
~ Explore future manufacturing paradigms for antibody-based therapeutics